Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors

about

Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors

Item

http://www.wikidata.org/entity/Q56373623

description

scientific article published on 02 July 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Chromogranin A: From Laborator ...... nts with Neuroendocrine Tumors

@en

Chromogranin A: From Laborator ...... nts with Neuroendocrine Tumors

@nl

type

Item

label

Chromogranin A: From Laborator ...... nts with Neuroendocrine Tumors

@en

Chromogranin A: From Laborator ...... nts with Neuroendocrine Tumors

@nl

prefLabel

Chromogranin A: From Laborator ...... nts with Neuroendocrine Tumors

@en

Chromogranin A: From Laborator ...... nts with Neuroendocrine Tumors

@nl

P1476

Chromogranin A: From Laborator ...... nts with Neuroendocrine Tumors

@en

P2093

Andrea Isidori

http://www.w3.org/2001/XMLSchema#string

Andrea Lania

http://www.w3.org/2001/XMLSchema#string

Andrea Lenzi

http://www.w3.org/2001/XMLSchema#string

Francesca Rota

http://www.w3.org/2001/XMLSchema#string

Laura Rizza

http://www.w3.org/2001/XMLSchema#string

Paola Di Giacinto

http://www.w3.org/2001/XMLSchema#string

Paolo Zuppi

http://www.w3.org/2001/XMLSchema#string

P2860

The catecholamine release-inhibitory "catestatin" fragment of chromogranin a: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses

Identification of a chromogranin A domain that mediates binding to secretogranin III and targeting to secretory granules in pituitary cells and pancreatic beta-cells

The chromogranin-secretogranin family

Gastroenteropancreatic neuroendocrine tumours

Molecular cloning and primary structure of human chromogranin A (secretory protein I) cDNA

The primary structure of human chromogranin A and pancreastatin

Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network.

Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management.

Everolimus for advanced pancreatic neuroendocrine tumors.

Carcinoid tumours. Frequency in a defined population during a 12-year period.

P304

8126087

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2018/8126087

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

Davide Campana

Roberto Baldelli

P577

2018-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30057604

http://www.w3.org/2001/XMLSchema#string

P921

endocrinology

P932

6051263

http://www.w3.org/2001/XMLSchema#string